Stock Market Reviews

Read and share opinions on RANI (Rani Therapeutics Holdings, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stoc

Latest News

• RANI: Third Quarter Results
  Nov 10, 2025
• Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
  Nov 6, 2025
• Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025
  Oct 30, 2025
• H.C. Wainwright Initiates Rani Therapeutics (RANI) with Buy and $11 PT on RaniPill Potential
  Oct 26, 2025
• Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors
  Oct 23, 2025
• Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
  Oct 23, 2025
• RANI: Chugai Deal Announced
  Oct 20, 2025
• Rani Therapeutics (RANI): Examining Valuation After Landmark Chugai Deal and $60M Funding Boost
  Oct 20, 2025
• Rani Therapeutics (RANI) Is Up 257.9% After $1.08 Billion Chugai Deal and $60M Fundraise—What’s Changed
  Oct 18, 2025
• Top Midday Gainers
  Oct 17, 2025
• Why Rani Therapeutics (RANI) Stock Is Soaring Friday?
  Oct 17, 2025
• Rani Therapeutics Enters Into Up to $1.09 Billion Collaboration, License Deal With Chugai Pharmaceutical -- Shares Rise Premarket
  Oct 17, 2025
• Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
  Oct 17, 2025
• Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing
  Oct 17, 2025
• RANI: Second Quarter Financial Results
  Aug 12, 2025
• Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update
  Aug 7, 2025
• Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering
  Jul 15, 2025
• Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery
  Jul 14, 2025
• Rani Therapeutics Announces Research Agreement with Chugai
  May 19, 2025